5.86
-0.18 (-2.98%)
| Previous Close | 6.04 |
| Open | 6.00 |
| Volume | 1,006,571 |
| Avg. Volume (3M) | 517,057 |
| Market Cap | 157,153,248 |
| Price / Book | 1.44 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -4.07 |
| Total Debt/Equity (MRQ) | 0.08% |
| Current Ratio (MRQ) | 7.75 |
| Operating Cash Flow (TTM) | -101.30 M |
| Levered Free Cash Flow (TTM) | -57.88 M |
| Return on Assets (TTM) | -31.92% |
| Return on Equity (TTM) | -42.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Cybin Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.0 |
| Average | -0.13 |
|
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 207.96% |
| % Held by Institutions | 42.41% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Deep Track Capital, Lp | 30 Jun 2025 | 1,529,987 |
| Acorn Capital Advisors, Llc | 30 Jun 2025 | 734,394 |
| Sphera Funds Management Ltd. | 30 Jun 2025 | 398,309 |
| Advisorshares Investments Llc | 30 Jun 2025 | 88,383 |
| Knott David M Jr | 30 Jun 2025 | 66,880 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |